Rapport Therapeutics, Inc. (RAPP)
NGM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Rapport Therapeutics Reports Cash Runway and RAP-219 Trial Progress
# 🧾 What This Document Is This is Rapport Therapeutics' **Annual Report to Shareholders (ARS)**. Think of it as the company's yearly "report card" and "state of the union" combined into one document, sent directly to its investors. It's designed to give a comprehensive, investor-friendly overview
RAPP reports 68% sustained seizure reduction with RAP-219 follow-up data
# 📄 What This Document Is 📰 This filing is a detailed summary of results presented at a major medical conference, the 2026 American Academy of Neurology (AAN) Annual Meeting. It's not a formal SEC filing, but an official presentation of scientific data about the company's lead drug, RAP-219. Bec
SEC filings
All filings →Insider trades
All insider trades →Rapport Therapeutics, Inc. has no reported insider trades in the last 90 days.